Tadao Ishida

13PUBLICATIONS
68CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyGene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Feb 27, 2026
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu

|Feb 26, 2026
Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives.

Hiroshi Yasui, Noriko Doki, Wei Yan

|Feb 19, 2026
Assessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database.

Hiroshi Handa, Tadao Ishida, Shuji Ozaki

|Jan 09, 2026
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Hiroshi Yasui, Masashi Idogawa, Tadao Ishida

|Jun 03, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Sikander Ailawadhi, Ivan Špička, Andrew Spencer

|May 09, 2025
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM.

Shinsuke Iida, Kazutaka Sunami, Shigeki Ito

Pageof 3

Frequent Collaborators

7 joint publications

Shinsuke Iida

3 joint publications

Masaki Ri

2 joint publications

Hartmut Goldschmidt

2 joint publications

Hiroshi Yasui